StockNews.AI
MLTX
StockNews.AI
1 min

MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

1. MoonLake's shares fell over 80% due to trial failures. 2. The first trial showed significant, but below-expectations results. 3. The second trial failed to meet its primary endpoint entirely. 4. Faruqi & Faruqi is investigating potential claims against MoonLake. 5. Market skepticism about the drug's regulatory and commercial future is rising.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The drastic share price drop over 80% signals severe investor confidence erosion, similar to past biotech failures where negative trial results led to sharp declines.

How important is it?

The article directly addresses MoonLake’s severe financial impact and ongoing investigations, indicating a critical moment for investor sentiment.

Why Short Term?

Given the immediate reaction to trial data, MLTX's price may remain pressured in the upcoming weeks as investors reassess valuation and company potential.

Related Companies

MLTXXLRNAPLS
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options If you suffered significant losses in MoonLake stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. Moonlake Immunotherapeutics saw its shares plummet over 80% on Monday after disappointing results from two late-stage trials of its experimental drug, sonelokimab, for hidradenitis suppurativa. While one study showed a statistically significant improvement over placebo, the margin of benefit fell short of investor expectations. The second trial failed to meet its primary endpoint entirely, with the company citing an unexpectedly high placebo response. The underwhelming data has cast doubt on the drug's regulatory path and commercial potential, prompting skepticism from analysts and a sharp market sell-off. To learn more about the MoonLake investigation, go to www.faruqilaw.com/MLTX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5cffc24f-1f2f-4a65-9fc1-400954361ba2

Related News